Phosphenes (Photopsia): What They Are, What to Do, and When to Worry

What Is a Phosphene?

A phosphene (also called photopsia) is the medical term for the anomalous perception of flashes of light within the visual field, in the absence of an actual external light source producing them. In other words, your eye or brain is generating the experience of light where none truly exists. People who experience phosphenes may describe them in a variety of ways, including:

• Brief flashes or streaks of light
• Flickering or sparkling lights
• Shimmering or trembling luminous shapes
• Floating forms or arcs of light
• Moving spots or points of light
• Sparks appearing at the edge of vision

The duration of each individual flash is typically less than one second. The shape of the perceived light is most often curvilinear, arc-shaped, or ring-like, though it can vary considerably between individuals and underlying causes. Phosphenes may appear in one eye or both eyes, but they are rarely synchronized between the two eyes simultaneously, which can help distinguish them from other types of visual phenomena.

It is important to understand that phosphenes are not a disease in themselves. They are a symptom, a signal produced by the visual system indicating that something is stimulating or irritating the light-sensing pathway, whether that is the retina, the optic nerve, or the visual cortex of the brain. Identifying the underlying cause is therefore the essential clinical task.

Phosphenes must also be carefully distinguished from myodesopsias, another common visual phenomenon that patients sometimes confuse with photopsia. Myodesopsias, colloquially known as “floaters”, appear as drifting spots, threads, cobwebs, or shadows that move across the visual field and seem to float in front of the eye. They are caused by small clumps or strands of material within the vitreous humor, the gel-like substance that fills the interior of the eye, and are generally distinct from the bright, flashing quality of true phosphenes.

The Physics and Physiology of Phosphenes

To understand why phosphenes occur, it helps to know a little about how the visual system works. The retina, a thin layer of neural tissue lining the interior back surface of the eye, contains specialized photoreceptor cells called rods and cones. These cells are designed to respond to photons of light, converting light energy into electrical signals that travel via the optic nerve to the visual processing centers in the brain.

However, retinal cells can also be triggered by stimuli other than light. Any sufficiently forceful mechanical, electrical, or chemical stimulus applied to the retina or along the visual pathway can produce the same electrical discharge that light would generate, and the brain, having no way to distinguish the source of the signal, interprets it as light. This is the fundamental mechanism behind phosphenes. Pressure on the eye (such as rubbing your closed eyes firmly), rapid eye movements, certain drugs, abnormal traction on the retina, electrical stimulation, or disrupted blood flow to the visual cortex can all generate phosphenes through this shared mechanism.

---

What Are the Most Common Causes?

Phosphenes arise from abnormal stimulation of the cells responsible for light perception, most often in the retina or visual cortex. Alterations in the vitreous body, the gel-like substance filling the eye, are among the most frequent triggers, as they can exert mechanical traction on the retina and cause it to fire electrical signals that the brain interprets as flashes of light.

In many cases, phosphenes are a momentary and essentially harmless phenomenon, triggered by:

• Looking directly at or being exposed to a strong light source, such as the sun, a camera flash, or a bright lamp. This is the most everyday form of phosphene, experienced by virtually everyone and of no clinical significance.
• Rapid or forceful eye movements, especially in darkness. When the eye moves quickly, the vitreous humor can momentarily exert traction on the retina, triggering a brief flash. This is why some people see brief flashes of light when they move their eyes quickly in a dark room.
• Standing up quickly from a lying or sitting position. A rapid drop in blood pressure (orthostatic hypotension) transiently reduces blood flow to the brain and retina, sometimes producing a brief phosphene or darkening of vision. This is a common and generally benign experience in young adults and is distinct from pathological causes.
• Rubbing the eyes with moderate to firm pressure, which mechanically stimulates the retinal cells.
• Blows to the head or eye, even relatively minor ones, which produce the well-known colloquial expression “seeing stars”. This too is mechanical stimulation of the retina or visual cortex.

These physiological phosphenes require no treatment and carry no clinical significance. However, in other patients, phosphenes may be the presenting manifestation of an underlying pathological condition affecting the eye, the optic nerve, or the brain. Identifying when phosphenes fall into this category is the central clinical challenge.

Migraine with Aura

The most common pathological cause of recurrent phosphenes is almost certainly migraine with aura. Migraine is a complex neurological disorder affecting approximately 15% of the global population, and roughly one-third of migraine sufferers experience an aura, a set of neurological symptoms that typically precede or accompany the headache phase by 20 to 60 minutes.

Visual aura is the most common type, occurring in up to 90% of those who have aura of any kind. Classic visual aura in migraine typically presents as a scintillating scotoma: a crescent-shaped or arc-shaped region of flickering, shimmering, or zigzag lights (sometimes described as fortification spectra or teichopsia, resembling the angular walls of a medieval fortress) that gradually expands across the visual field over the course of 20 to 30 minutes and then resolves.

Migraine aura typically affects both eyes simultaneously (because it originates in the visual cortex of the brain, which processes input from both eyes), though one side of the visual field is usually more prominently affected than the other. This bilateral but asymmetric quality can help distinguish aura from monocular visual symptoms caused by retinal pathology, which affect only one eye.

It is important to note that ophthalmoplegic migraine (also called ocular or retinal migraine) is a distinct and rarer subtype in which visual symptoms, including phosphenes, arise from reduced blood flow in the retinal or ciliary arteries, producing symptoms that affect only one eye rather than one visual field. This distinction matters clinically because truly monocular visual symptoms raise different diagnostic concerns than hemianopic symptoms.

Posterior Vitreous Detachment

Posterior vitreous detachment (PVD) is one of the most common eye conditions seen by ophthalmologists and accounts for the majority of cases in which patients seek medical evaluation specifically because of new-onset photopsia.

The vitreous humor is a clear, gel-like substance that fills approximately 80% of the eye’s interior volume. In youth, the vitreous is firmly adherent to the retina. With advancing age, the vitreous gradually liquefies and shrinks, eventually separating from the retina in a process called posterior vitreous detachment. PVD is an essentially universal aging phenomenon, occurring in the majority of people over the age of 60 and in most people over 70 to 80.

When PVD occurs gradually and smoothly, it may cause floaters (from condensations and strands in the now-separated vitreous) but little else. However, when the vitreous separates more abruptly, or when adhesions between the vitreous and certain areas of the retina cause the vitreous to tug on the retinal surface as it detaches, this mechanical traction stimulates the retinal photoreceptors, producing flashes of light (phosphenes). These vitreous-related phosphenes are typically described as brief flickers or arcs of light, most noticeable in dim lighting or when the eyes move.

PVD itself is generally a benign process and does not threaten vision. However, in a small but clinically important proportion of cases (estimated at approximately 10 to 15% of symptomatic PVDs), the vitreous traction is strong enough to tear the retina as it separates, creating a retinal tear, which in turn can progress to retinal detachment, a sight-threatening emergency. This is why new-onset photopsia, even without other alarming features, always warrants timely ophthalmological evaluation to rule out retinal tear.

Retinal Detachment

Retinal detachment is a serious, sight-threatening emergency that requires prompt surgical treatment to preserve vision. It occurs when the neurosensory retina (the light-sensitive layer of the eye) separates from the underlying retinal pigment epithelium and choroidal vasculature that supply it with oxygen and nutrients. Once detached, the deprived retinal cells begin to die, and if the detachment is not repaired in time, permanent and irreversible vision loss ensues.

The most common type, rhegmatogenous retinal detachment, occurs when a tear or hole in the retina allows fluid from the vitreous to seep beneath the retina and gradually lift it away from its normal position. Such tears frequently arise in the context of PVD when the separating vitreous generates enough traction to rip through the retinal tissue.

The classic warning signs of retinal detachment that patients should be aware of include:

• A sudden significant increase in floaters, particularly if they appear as a shower of new spots or a cobweb-like veil
• New or worsening flashes of light (phosphenes), especially if they are more frequent, persistent, or intense than before
• A curtain, shadow, or dark veil that appears to descend over part of the visual field, progressively obscuring vision from one side
• Blurring of central vision if the macula (the central part of the retina responsible for detailed vision) becomes involved

Any of these symptoms, particularly the appearance of a curtain or shadow in the visual field, constitutes an ophthalmological emergency. The patient should seek same-day or emergency evaluation by an ophthalmologist. Early surgical intervention (with laser photocoagulation, cryotherapy, pneumatic retinopexy, scleral buckling, or vitrectomy depending on the characteristics of the detachment) can successfully reattach the retina and preserve vision in the majority of cases.

Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in people over the age of 50 in high-income countries. It primarily affects the macula, the small central region of the retina responsible for detailed central vision, color perception, and face recognition.

AMD exists in two forms: dry (atrophic) AMD, which accounts for approximately 85 to 90% of cases and progresses slowly, and wet (neovascular) AMD, which is less common but much more rapidly destructive due to the growth of abnormal new blood vessels beneath and into the retina (choroidal neovascularization). These fragile new vessels leak fluid and blood, causing rapid distortion and loss of central vision.

Phosphenes can occur in AMD, particularly in wet AMD where subretinal fluid and hemorrhage mechanically disturb the retina. Associated visual symptoms include distortion of straight lines (metamorphopsia, classically tested with the Amsler grid), a central dark spot (scotoma), and difficulty reading, recognizing faces, or performing tasks requiring fine visual detail. AMD does not cause complete blindness, as peripheral vision is preserved, but the loss of central vision is severely disabling. Anti-VEGF intravitreal injections (such as ranibizumab, bevacizumab, or aflibercept) have revolutionized the treatment of wet AMD, preventing or slowing vision loss in most patients when administered regularly.

Diabetic Retinopathy

Diabetic retinopathy is a progressive complication of diabetes mellitus caused by chronic damage to the small blood vessels of the retina from persistently elevated blood glucose levels. It is the leading cause of new blindness in working-age adults in developed countries, and affects the majority of diabetic patients to some degree after 20 years of disease.

In advanced proliferative diabetic retinopathy, abnormal new blood vessels grow into the vitreous (neovascularization). These fragile vessels can bleed into the vitreous (vitreous hemorrhage), causing a sudden shower of floaters or a red-tinged haze of vision. The associated disturbance to the vitreous-retinal interface can also produce phosphenes. Tractional retinal detachment, caused by fibrous scar tissue pulling on the retina, is another potential complication of advanced diabetic retinopathy.

Prevention through optimal glycemic control, blood pressure management, and regular ophthalmological screening is far more effective than any available treatment for established retinopathy. When treatment is needed, options include laser photocoagulation (panretinal photocoagulation), intravitreal anti-VEGF injections, and vitreoretinal surgery.

Optic Neuritis

Optic neuritis is an inflammatory condition affecting the optic nerve, the cable that transmits visual information from the retina to the brain. It is strongly associated with multiple sclerosis (MS) and in many cases is the first clinical manifestation of the disease, though it can also occur in other inflammatory and autoimmune conditions including neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

Phosphenes in optic neuritis are characteristically elicited or worsened by eye movement, a distinctive clinical feature. Patients often report that moving their eyes rapidly in any direction triggers brief flashes of light. This phenomenon, sometimes called photopsia of ocular movement, is caused by mechanical stimulation of the inflamed and hypersensitive optic nerve as the extraocular muscles tug on it during movement.

Additional characteristic symptoms of optic neuritis include:

• Painful eye movement, typically described as a dull aching pain behind or around the eye that worsens when the eye is moved
• Subacute, progressive visual loss in the affected eye developing over hours to days
• Reduced color saturation, particularly for red hues (dyschromatopsia), which patients may notice as colors appearing washed out or duller
• Reduced contrast sensitivity
• Uhthoff’s phenomenon: temporary worsening of visual symptoms with heat exposure (such as a hot shower or exercise), a characteristic feature of demyelinating optic neuritis

Optic neuritis is typically treated with high-dose intravenous corticosteroids (methylprednisolone 1 gram per day for 3 days), which accelerate recovery but do not affect the final visual outcome. Most patients recover vision substantially, though subtle deficits in color vision and contrast sensitivity may persist. In patients with MS or other demyelinating conditions, disease-modifying therapy is an important consideration to reduce the risk of further neurological events.

Stroke and Transient Ischemic Attack

Visual phosphenes can be a manifestation of stroke or transient ischemic attack (TIA) when the ischemic event affects the occipital lobe, the area of the brain located at the back of the skull that is responsible for processing visual information.

When blood flow to the occipital cortex is abruptly reduced or interrupted, the visual neurons can fire abnormally, generating phosphenes. These may appear as shimmering lights, colored flashes, or visual distortions. As the ischemic damage progresses or fluctuates, the phosphenes may give way to visual field defects, most commonly a homonymous hemianopia (loss of the same half of the visual field in both eyes) corresponding to the side of the brain affected.

Accompanying symptoms that strongly suggest a vascular neurological event include:

• Sudden-onset blurred or dimmed vision
• Loss of vision affecting part or all of one eye or one visual field
• Visual hallucinations (more complex visual experiences than simple flashes)
• Sudden severe headache, particularly described as “the worst headache of my life” (suggesting subarachnoid hemorrhage)
• Weakness, numbness, or paralysis of the face, arm, or leg on one side of the body
• Slurred speech or difficulty finding words
• Sudden loss of balance or coordination

Stroke and TIA are medical emergencies. If any of these symptoms accompany visual phosphenes, the patient should call emergency services immediately. The acronym FAST (Face drooping, Arm weakness, Speech difficulty, Time to call emergency services) is a widely used tool to help the public recognize stroke symptoms and act without delay. Time is of critical importance: every minute of delay in stroke treatment leads to the death of approximately 1.9 million neurons.

Other Pathological Causes

Several additional conditions less frequently associated with phosphenes are worth noting:

• Sensory deprivation: Prolonged absence of visual input, as can occur in extreme darkness or following sudden blindness from any cause, can paradoxically generate visual phenomena including phosphenes. This is thought to arise from spontaneous or disinhibited activity of visual neurons in the cortex deprived of their normal sensory input, a phenomenon related to the Charles Bonnet syndrome seen in people with severe vision loss.

• Preeclampsia: The development of phosphenes has been described in severe cases of preeclampsia, a dangerous hypertensive disorder of pregnancy. Visual disturbances in the context of preeclampsia, including flashes of light, blind spots, or sudden severe visual changes, represent an obstetric emergency and should prompt immediate medical evaluation. These visual symptoms arise from hypertensive damage to the cerebral vasculature, retina, or both, and may herald imminent eclampsia (seizures) or other life-threatening complications.

• Medication side effects: Phosphenes are a recognized adverse effect of certain pharmacological agents, including clomiphene citrate (clomifene, used for ovulation induction), ivabradine (a heart rate-lowering medication), phosphodiesterase-5 inhibitors such as sildenafil (Viagra) in high doses, and occasionally certain antimalarial drugs, antiepileptics, and chemotherapeutic agents. If you notice new-onset visual symptoms after starting a new medication, always report this to your prescribing physician.

• Retinitis pigmentosa: A group of inherited retinal dystrophies causing progressive photoreceptor degeneration, often presenting with night blindness, tunnel vision, and eventually severe visual loss. Photopsia can occur as a symptom of active retinal degeneration.

• Cardiac arrhythmias and hemodynamic instability: Any condition that severely or transiently reduces cerebral blood flow, including significant cardiac arrhythmias, severe hypotension, or vasovagal syncope, can produce brief visual phenomena including phosphenes and blackouts.

---

When to See a Doctor

The clinical significance of phosphenes spans the full spectrum from completely benign and self-limiting to a sign of imminent permanent vision loss or life-threatening neurological emergency. Making this distinction is not always easy for patients, which is why certain situations always warrant medical evaluation regardless of how minor the symptoms may seem.

As a general rule: phosphenes that arise from an obvious and immediately identifiable benign cause (looking at a bright light source, rubbing the eyes, standing up quickly) are not a cause for concern and do not require medical assessment. All other new-onset phosphenes should be reported to a healthcare provider.

Situations Requiring Emergency Assessment

The following scenarios require immediate emergency evaluation, either at an emergency department or by urgent same-day ophthalmological assessment:

• A sudden dramatic increase in the number or intensity of flashes, particularly when associated with a shower of new floaters. This combination is a classic warning sign of a new retinal tear or early retinal detachment and must be assessed the same day.
• Appearance of a curtain, shadow, or dark veil across any part of the visual field. This symptom strongly suggests actual retinal detachment and is an ophthalmological emergency. Every hour of delay increases the risk of the detachment extending to involve the macula, with permanent central vision loss.
• Phosphenes accompanied by sudden-onset neurological symptoms such as limb weakness, facial drooping, speech difficulty, severe sudden headache, or sudden loss of balance. These suggest stroke or TIA and require emergency services to be called immediately.
• Phosphenes in the context of pregnancy accompanied by high blood pressure, severe headache, or other symptoms of preeclampsia. This is an obstetric emergency.
• Phosphenes associated with significant eye trauma, particularly with loss of vision, visible blood within the eye, or deformation of the eye.
• New-onset phosphenes in any patient with a history of retinal disease, prior retinal detachment in the other eye, high myopia (short-sightedness), or diabetes. These patients are at higher baseline risk of serious retinal complications and should be assessed urgently.

Situations Requiring Prompt but Non-Emergency Evaluation

• New-onset phosphenes without accompanying neurological symptoms or visual field defects, particularly in patients over 50, should be assessed by an ophthalmologist within days rather than weeks, to rule out PVD with retinal tear or other retinal pathology.
• Recurrent phosphenes in a known migraine sufferer that follow the typical pattern of their usual aura and resolve completely without new features may not require urgent assessment but should be mentioned at the next scheduled appointment with the treating physician.
• Phosphenes that coincide with starting a new medication should be reported promptly to the prescribing physician.
• Any persistent phosphenes that do not resolve or that are gradually worsening should be investigated, even if they seem mild.

---

What to Do

Since photopsia is a symptom and not a disease in itself, the treatment of phosphenes is directed entirely at the underlying cause. There is no specific intervention that treats the flash of light itself independently of what is producing it.

Initial Steps When You Experience Phosphenes

1. Assess the context. Ask yourself: Did I just look at a bright light source? Did I just stand up quickly? Did I rub my eyes? If yes, and if the phosphenes resolve completely within seconds and do not recur, no action is likely needed.

2. Check for accompanying symptoms. Immediately assess whether you have any of the following:

• New floaters, particularly numerous or prominent ones
• A shadow, curtain, or dark area in your vision
• Reduced vision in any area of the visual field
• Headache, particularly severe or sudden-onset
• Neurological symptoms (weakness, numbness, speech problems, balance issues)
• Eye pain

The presence of any of these alongside phosphenes significantly raises the urgency of medical evaluation.

3. Do not drive if your visual symptoms are ongoing or fluctuating. This applies regardless of the suspected cause, as any significant visual disturbance impairs driving safety.

4. Seek the appropriate level of care. As described above, emergency symptoms require emergency care. Other new-onset phosphenes require an appointment with an ophthalmologist or, at minimum, a general practitioner who can assess and refer appropriately.

Cause-Specific Management

Posterior vitreous detachment (PVD): The condition itself requires no treatment. However, because PVD carries a risk of associated retinal tear, ophthalmological evaluation is necessary. If no retinal tear is found, the patient is usually reassured and asked to return immediately if symptoms worsen (more floaters, more flashes, or a visual field defect). If a retinal tear is found but the retina is still attached, laser photocoagulation or cryotherapy can seal the tear and prevent progression to detachment.

Retinal detachment: Requires urgent surgical repair. The method depends on the type, location, and extent of the detachment and includes pneumatic retinopexy (injection of a gas bubble into the eye), scleral buckling (surgery to indent the eye wall from outside), pars plana vitrectomy (surgical removal of the vitreous), or a combination of these approaches. Vision outcomes are best when the macula has not detached, underscoring the importance of prompt diagnosis and treatment.

Migraine with aura: Acute migraine treatment with analgesics (paracetamol, NSAIDs), triptans, or anti-emetics is directed at the headache phase; the aura itself does not require specific treatment and resolves spontaneously. Preventive migraine therapy (beta-blockers, topiramate, valproate, CGRP receptor antagonists, or other agents) is considered when attacks are frequent, severely disabling, or when the aura is particularly prolonged or atypical. Patients with migraine aura who smoke are at increased risk of ischemic stroke and should be advised to stop smoking. Combined oral contraceptives require careful consideration in women with migraine with aura due to an increased stroke risk.

Optic neuritis: High-dose intravenous corticosteroids accelerate recovery. Further neurological investigation with MRI of the brain and spinal cord is typically indicated to assess for evidence of multiple sclerosis or other demyelinating disease, as early disease-modifying therapy can significantly reduce the risk of further relapses.

Diabetic retinopathy: Optimal glycemic control and blood pressure management are the cornerstones of prevention and slowing of progression. Treatment of advanced retinopathy includes intravitreal anti-VEGF injections, laser photocoagulation, and in some cases vitreoretinal surgery.

Age-related macular degeneration: Wet AMD is treated with regular intravitreal anti-VEGF injections. Dry AMD currently has no effective treatment to reverse existing damage, though supplements based on the AREDS2 formula (containing lutein, zeaxanthin, vitamins C and E, and zinc) have been shown to reduce the risk of progression to advanced stages in intermediate AMD. Smoking cessation, a healthy diet rich in leafy green vegetables, and protection of the eyes from ultraviolet light are recommended preventive measures.

Stroke and TIA: Emergency management of acute ischemic stroke includes intravenous thrombolysis with alteplase (if within the treatment window) and mechanical thrombectomy (if within an extended window and anatomically feasible). Secondary prevention involves antiplatelet or anticoagulant therapy, management of vascular risk factors (hypertension, diabetes, hyperlipidemia, atrial fibrillation), and lifestyle modification. TIA is a medical emergency requiring urgent assessment (including brain imaging and vascular studies) and initiation of secondary preventive treatment to reduce the risk of subsequent completed stroke.

Medication-induced phosphenes: If a medication is identified as the likely cause, the physician may reduce the dose, switch to an alternative agent, or in some cases discontinue the offending drug, depending on the clinical necessity and available alternatives.

Preeclampsia: Visual symptoms in the context of preeclampsia require immediate obstetric assessment. Management of severe preeclampsia typically involves blood pressure control, seizure prophylaxis with magnesium sulfate, corticosteroids for fetal lung maturation if preterm, and delivery of the baby and placenta, which is the definitive treatment.

Lifestyle Considerations

While lifestyle measures cannot cure most of the serious conditions that cause phosphenes, certain behaviors may reduce the risk of developing some of them:

• Protecting the eyes from UV radiation with quality sunglasses (UV400 protection) reduces the long-term risk of cataracts, macular degeneration, and other phototoxic damage to ocular structures.
• Controlling blood pressure, blood glucose, and cholesterol through diet, regular physical activity, and appropriate medication reduces the risk of vascular eye diseases including diabetic retinopathy, AMD, and vascular occlusions.
• Avoiding smoking, which is one of the most powerful modifiable risk factors for AMD, optic neuropathy, cataracts, and cerebrovascular disease.
• Maintaining a diet rich in green leafy vegetables, particularly those containing lutein and zeaxanthin (spinach, kale, broccoli), which are natural antioxidants that accumulate in the macula and may protect against AMD.
• Regular ophthalmological screening is particularly important for individuals with diabetes (annual dilated fundus examination), those over 60 years of age, individuals with high myopia, anyone with a personal or family history of retinal disease, and anyone who has previously experienced retinal detachment in the other eye.

---

Sources and Bibliography

• University of Iowa Eye Rounds - Photopsias: A Key Symptom in Retinal Disease
• Flaxel CJ, et al. “Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern”. Ophthalmology. 2020;127(1):P146-P181. PubMed
• Regillo CD, et al. “Retinal Detachment Preferred Practice Pattern”. Ophthalmology. 2020;127(1):P1-P52. PubMed
• Headache Classification Committee of the International Headache Society (IHS). “The International Classification of Headache Disorders, 3rd edition”. Cephalalgia. 2018;38(1):1-211. PubMed
• Olesen J. “Headache Classification Committee of the International Headache Society”. Lancet Neurology. 2018.
• Newman NJ, Biousse V. “Diagnostic approach to optic nerve disorders”. Clinical Ophthalmology. 2021.
• Age-Related Eye Disease Study Research Group. “A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8”. Archives of Ophthalmology. 2001;119(10):1417-1436. PubMed
• American Academy of Ophthalmology. “Preferred Practice Patterns: Age-Related Macular Degeneration”. 2019. Available at: https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp
• Powers WJ, et al. “2019 AHA/ASA Focused Update of the 2018 Guidelines for the Early Management of Acute Ischemic Stroke”. Stroke. 2019;50(12):e344-e418. PubMed
• Askie LM, et al. “Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data”. Lancet. 2007;369(9575):1791-1798. PubMed